Home / Articles / Rare disease medicines for children

Rare disease medicines for children: how Gulf families can access them

A guide for parents and pediatric specialists, with the rules and the medicines checked on 17 October 2026.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026. Sources accessed 17 October 2026.

The short answer

For a child with a rare disease, the first steps are a confirmed genetic or laboratory diagnosis and a pediatric specialist's plan. If a US-approved medicine is not registered at home, the treating hospital can request it for the named child. Gene therapies are given at qualified centers, often abroad. Saudi Arabia's new rare disease framework points families to its Named Patient and Special Access Programs.

  • First step: A confirmed diagnosis and a specialist's plan.
  • Saudi Arabia: Rare disease framework in force from 5 September 2026.
  • Medicines: Hospital named-patient or special access request.
  • Gene therapies: Given at qualified treatment centers.

Rare disease, by the numbers

The NIH's Genetic and Rare Diseases Information Center (GARD) provides information on thousands of rare diseases for patients and families, including where to find specialists and support.[1]

Saudi Arabia's SFDA defines a rare disease as one affecting fewer than 1 in 2,000 people in the Kingdom, under its Regulatory Framework for Rare Diseases Drugs, in force from 5 September 2026.[2]

Saudi Arabia's 2026 rare disease framework

We give you a written timeline estimate for your case before you commit.[2]

In Saudi Arabia, the SFDA Special Access Program lets a patient with a serious or immediately life-threatening condition receive a medicine that is not registered when no comparable alternative exists. The request comes from the manufacturer or sponsor, or from the licensed treating physician if there is no sponsor. We give you a written timeline estimate for your case before you commit.[3]

Examples of US-approved treatments for children

  • Zolgensma (onasemnogene abeparvovec): one-time gene therapy for children under two years with spinal muscular atrophy and bi-allelic SMN1 mutations.[4]
  • Kebilidi (eladocagene exuparvovec): gene therapy for adults and children with AADC deficiency.[5]
  • Lenmeldy (atidarsagene autotemcel): gene therapy for children with pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile metachromatic leukodystrophy.[6]
  • Kresladi (marnetegragene autotemcel): gene therapy for children with severe leukocyte adhesion deficiency-I without an HLA-matched sibling donor.[7]
  • Skysona (elivaldogene autotemcel): gene therapy to slow neurologic decline in boys 4 to 17 years with early, active cerebral adrenoleukodystrophy and no HLA-matched donor.[8]
  • Fayuvi (rebisufligene etisparvovec): gene therapy for neurologic manifestations of MPS IIIA (Sanfilippo syndrome type A) in children with preserved neurodevelopmental function.[9]
  • Daybue (trofinetide): Rett syndrome in patients 2 years and older.[10]
  • Voxzogo (vosoritide): to increase linear growth in children with achondroplasia with open epiphyses (accelerated approval).[11]
  • Strensiq (asfotase alfa): perinatal, infantile and juvenile-onset hypophosphatasia.[12]

Gene therapies: treatment at a center

Gene therapies such as Zolgensma, Lenmeldy and Kebilidi appear on FDA's list of approved cellular and gene therapy products. They are given once, through a specialized procedure, at centers the manufacturer has qualified.[13]

The pediatric specialist refers the child, the center confirms eligibility, and the family plans funding and travel. Ask early, because eligibility can depend on age or disease stage.

Practical steps for parents

  • Ask for the genetic or laboratory report that confirms the diagnosis, and keep a translated copy.
  • Ask the specialist which US-approved treatment fits your child's exact diagnosis and age, and read the US label together.
  • Ask the hospital whether the medicine is registered locally, and if not, whether it will request it as a named patient.
  • For gene therapy, ask which centers offer it and what tests they need before referral.
  • Ask your insurer or government program about funding before travel or treatment is booked.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help families and treating doctors understand the route, prepare the documents the regulator or hospital asks for, arrange supply from the US once approval is in place, and keep everyone updated. We do not diagnose, prescribe or decide what a regulator approves.

We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them. Your coordination fee is quoted in writing for your case before you commit. No hidden charges. We give you a written timeline estimate for your case before you commit.

Ask us about a medicine

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Include the country code, for example +966 or +971.
Message us on WhatsApp

No account needed. We reply within one business day. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for my child's rare disease?

Some rare diseases now have FDA-approved medicines or gene therapies. The pediatric specialist matches the child's exact diagnosis and age to the US label.

What does Saudi Arabia's rare disease framework change?

It defines rare disease as fewer than 1 in 2,000 people, offers orphan designation, and points to the Named Patient and Special Access Programs for unregistered rare-disease medicines.

Can gene therapy be given at a local hospital?

Only if the manufacturer has qualified that center and the regulator allows it. Otherwise the child is referred to a qualified center, often abroad.

Who applies for an unregistered medicine for a child?

The treating hospital or physician. Parents provide consent and documents.

Where can parents find reliable information about a rare disease?

The NIH Genetic and Rare Diseases Information Center (GARD) provides information on rare diseases for patients and families, including where to find specialists and support.

Sources for these answers: [2, 3, 13, 1]

Sources

All sources were opened and checked on 17 October 2026. Rules and labels change, so the treating hospital or regulator confirms the current position before anything is filed.

  1. NIH Genetic and Rare Diseases Information Center (GARD): About (accessed 17 October 2026)
  2. SFDA: Regulatory Framework for Rare Diseases Drugs, version 1.0 (August 2026) (accessed 17 October 2026)
  3. SFDA: Special Access Program (SAP) guidance, version 1.0 (accessed 17 October 2026)
  4. US FDA: ZOLGENSMA product page (CBER) (accessed 17 October 2026)
  5. US FDA: KEBILIDI product page (CBER) (accessed 17 October 2026)
  6. US FDA: LENMELDY product page (CBER) (accessed 17 October 2026)
  7. US FDA: KRESLADI product page (CBER) (accessed 17 October 2026)
  8. US FDA: SKYSONA product page (CBER) (accessed 17 October 2026)
  9. US FDA: FAYUVI product page (CBER) (accessed 17 October 2026)
  10. DailyMed: Daybue (trofinetide) US prescribing information, version effective 4 September 2026 (accessed 17 October 2026)
  11. DailyMed: Voxzogo (vosoritide) US prescribing information, version effective 25 November 2025 (accessed 17 October 2026)
  12. DailyMed: Strensiq (asfotase alfa) US prescribing information, version effective 12 December 2025 (accessed 17 October 2026)
  13. US FDA: Approved Cellular and Gene Therapy Products (accessed 17 October 2026)

Related

This page is general information, not medical or legal advice. It does not replace advice from your own doctor or the regulator.

WhatsApp